Ask a doctor about a prescription for HYDROCHLOROTHIAZIDE AUROVITAS 50 mg TABLETS
Package Leaflet: Information for the User
Hydrochlorothiazide Aurovitas 50 mg Tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Hydrochlorothiazide Aurovitas belongs to a group of medicines called “diuretics”. Diuretics increase the amount of urine that is passed.
Hydrochlorothiazide is used in adults to treat:
Do not take Hydrochlorothiazide Aurovitas:
Warnings and precautions
Consult your doctor or pharmacist before taking Hydrochlorothiazide Aurovitas:
In chronic users of diuretics, a pseudo-Bartter syndrome may appear along with water retention in the body's tissues (edema).
During treatment with this medicine, you should drink sufficient amounts of liquid. Due to the increased loss of potassium, you should follow a potassium-rich diet (e.g., bananas, vegetables, nuts).
Sunlight or UV cabin exposure
If you have had sensitivity to sunlight due to this medicine and your doctor decided to continue treatment, you must protect your skin from the sun and not use UV tanning cabins (also see section 4 to know what to do if these side effects occur).
Blood tests
It is possible that your doctor will ask you to have blood tests done regularly during treatment to check your kidney function and especially your sodium, potassium, calcium, sugar (glucose), and uric acid levels in the blood.
Elderly patients (65 years and older)
In the treatment of elderly patients, attention should be paid to possible restrictions of kidney function (see section 3).
Other medicines and Hydrochlorothiazide Aurovitas
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Your doctor may need to change the dose and/or take other precautions if you are taking other medicines, especially if you are taking any of the following:
Hydrochlorothiazide Aurovitas with food and drinks
Do not consume alcohol while taking this medicine because it can cause orthostatic hypotension (a sudden drop in blood pressure that causes dizziness due to a change in position, e.g., standing up).
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Generally, your doctor will recommend that you take another medicine instead of hydrochlorothiazide because it is not recommended during pregnancy, except in rare cases where no other treatment can be used.
This medicine passes into the placenta and its use after the third month of pregnancy may cause serious harm to your baby.
Breastfeeding
Hydrochlorothiazide passes into breast milk. Do not take this medicine while breastfeeding unless your doctor tells you to.
Driving and using machines
Hydrochlorothiazide tablets have a mild or moderate influence on the ability to drive and use machines.
Even when used as directed, this medicine can affect your reflexes. Therefore, your ability to drive or operate machinery or work in places without solid support may be affected.
This is especially true at the start of treatment, when the dose is increased, the medication is changed, or when it is taken in combination with alcohol.
Doping test
Hydrochlorothiazide may produce a positive analytical result in a doping test.
Hydrochlorothiazide Aurovitas contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
Hydrochlorothiazide Aurovitas tablets are available in 3 doses: 12.5 mg, 25 mg, and 50 mg tablets.
Edema:
The recommended initial dose is 50 mg to 100 mg of hydrochlorothiazide per day.
The maintenance dose is usually 25 mg to 50 mg of hydrochlorothiazide per day.
High blood pressure (hypertension):
The currently recommended doses in arterial hypertension are 12.5 or 25 mg/day.
Elderly patients:
In the treatment of elderly patients (65 years or older), attention should be paid to possible restrictions of kidney function.
Use in children and adolescents
There is no experience in children and adolescents. Therefore, hydrochlorothiazide should not be administered to children and adolescents.
Method of administration
For oral use.
Swallow the tablets with a sufficient amount of liquid.
This medicine can be taken with or without food.
The tablets can be divided into equal doses.
Frequency of administration
This medicine has a diuretic effect (i.e., you will urinate more often). In view of this, it is better not to take the last dose at the end of the day to avoid waking up during the night. If you take your tablets as a single dose, take them in the morning.
Duration of treatment
Your doctor will tell you how long you should take this medicine.
Your doctor will perform periodic checks to ensure that the treatment has the expected effects. If you have any questions about the duration of treatment, consult your doctor or pharmacist.
If you take more Hydrochlorothiazide Aurovitas than you should
Contact your doctor or go immediately to the hospital emergency department if you experience nausea, drowsiness, muscle contractions, cardiac arrhythmias (irregular heartbeat), low blood pressure (identifiable by dizziness), confusion, or urinary problems.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Hydrochlorothiazide Aurovitas
If you forget to take a dose, you should take it as soon as you remember. Do not take a double dose to make up for forgotten doses, continue treatment as prescribed.
If you stop taking Hydrochlorothiazide Aurovitas
Do not stop treatment with hydrochlorothiazide unless your doctor tells you to. If you stop treatment, your blood pressure will not be controlled (see also “Duration of treatment”).
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Effects that require treatment interruption
You must stop treatment and consult a doctor or the hospital emergency department if you have a reaction to sunlight (skin reaction).
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister after CAD. The expiry date is the last day of the month indicated.
This medicine does not require any special temperature storage conditions.
Keep the blister in the outer packaging to protect it from light.
Keep the bottle in the original packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition ofHidroclorotiazida Aurovitas
Tablet core:lactose monohydrate, calcium hydrogen phosphate dihydrate, pregelatinized corn starch, corn starch, anhydrous colloidal silica, and magnesium stearate.
Appearance of the Product and Package Contents
Uncoated tablets, white to off-white in color, round in shape, with flat faces and a beveled edge, marked with "HC 50" on one face and a score line on the other face. The tablet can be divided into equal doses.
Hidroclorotiazida Aurovitas tablets are available in blister packs and PEAD bottles.
Blister pack:20, 30, 50, 60, 90, and 100 tablets.
PEAD bottle (for all doses):500 tablets.
Only certain package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Or
Arrow Generiques – Lyon
26 avenue Tony Garnier,
Lyon, 69007
France
Or
Generis Farmacêutica, S.A.
Rua João de Deus, 19
2700-487 Amadora
Portugal
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany HCT PUREN 50 mg Tabletten
Spain Hidroclorotiazida Aurovitas 50 mg tablets
Italy Idroclorotiazide Aurobindo
Netherlands Hydrochloorthiazide Aurobindo 50 mg, tablets
Poland Hydrochlorothiazide Aurovitas
Portugal Hidroclorotiazida Generis
Czech Republic Hydrochlorothiazide Aurovitas
Date of the last revision of this leaflet:March 2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es)
The average price of HYDROCHLOROTHIAZIDE AUROVITAS 50 mg TABLETS in October, 2025 is around 2.34 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for HYDROCHLOROTHIAZIDE AUROVITAS 50 mg TABLETS – subject to medical assessment and local rules.